Vadadustat is being developed to treat anemia in CKD patients. Credit: dream designs via FreeDigitalPhotos.net.

The US Food and Drug Administration (FDA) has allowed Sanofi Genzyme and Alnylam Pharmaceuticals to proceed with clinical trials of fitusiran, an investigational product candidate.

The FDA lifted the clinical hold on all of fitusiran studies, including the Phase II open-label extension (OLE) study and the ATLAS Phase III programme.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Fitusiran is being developed as an RNAi therapeutic to target antithrombin (AT) for treating patients suffering from haemophilia A and B.

The investigational candidate is formulated to reduce levels of AT to stimulate sufficient generation of thrombin for restoring haemostasis and preventing bleeding.

Sanofi has previously collaborated with Alnylam for the development and commercialisation of fitusiran.

“We are pleased with the FDA’s decision to lift the clinical hold, as fitusiran holds the potential to help improve the lives of people living with haemophilia.”

In September, Alnylam stopped fitusiran dosing in all ongoing trails after a patient with haemophilia A without inhibitors experienced a fatal thrombotic event during the Phase II OLE trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Alnylam and the FDA discussed the new clinical risk mitigation measures for fitusiran, and agreed on amended protocol-specified guidelines, additional investigator and patient education on decreased doses of replacement factor or bypassing agent for the treatment of breakthrough bleeds in the trials.

Alnylam Pharmaceuticals Fitusiran vice-president and general manager Akin Akinc said: “We are pleased with the FDA’s decision to lift the clinical hold, as fitusiran holds the potential to help improve the lives of people living with haemophilia.

“With the additional risk mitigation measures in place, we look forward to the continued late-stage development of fitusiran and expect to resume dosing around year-end.”